MgSO4 in Shivering Management
Magnesium sulfate should be used as a non-sedating adjunct for shivering suppression, but it is insufficient as monotherapy and requires combination with more effective agents like opioids, sedatives, or neuromuscular blockade to control clinically significant shivering.
Efficacy and Clinical Role
Magnesium sulfate has only modest clinical effects on shivering control 1. The 2023 European Heart Journal guidelines clearly state that while MgSO4 is widely available with few side effects, it only slightly reduces the shivering threshold and has limited clinical impact 1. Research confirms this: a controlled study in healthy volunteers demonstrated that magnesium reduced the shivering threshold by only 0.3°C (from 36.6°C to 36.3°C), which is clinically unimportant for therapeutic hypothermia 2.
When used alone, magnesium and acetaminophen are typically insufficient to suppress clinically significant shivering 1. They are valued primarily for their excellent safety profile, not their potency.
Dosing Protocol
Standard Dosing for Shivering Management
Based on guideline recommendations and FDA labeling:
- Bolus dose: 2-4 g IV 1
- Infusion rate: 1 g/hour 1
- Administration frequency: Every 2-4 hours as needed 1
The FDA label specifies that IV injection rate should generally not exceed 150 mg/minute (1.5 mL of 10% concentration) 3. Solutions must be diluted to 20% concentration or less prior to IV infusion 3.
Research-Based Dosing Considerations
Recent studies in postoperative shivering suggest:
- 50 mg/kg IV bolus over 20 minutes was more effective than 30 mg/kg for preventing high-grade shivering (88% vs 60% shivering-free) 4
- 25 mg/kg vs 50 mg/kg showed equivalent efficacy in another study, with 90.9% vs 95.5% remaining shivering-free 5
However, these postoperative doses differ from the guideline-recommended approach for therapeutic hypothermia settings.
Monitoring Requirements
Critical safety threshold: Maintain serum magnesium levels below 4 mg/dL 1.
Clinical Monitoring Parameters
- Deep tendon reflexes: Begin to diminish when levels exceed 4 mEq/L; may be absent at 10 mEq/L 3
- Respiratory function: Respiratory paralysis becomes a hazard at 10 mEq/L 3
- Patellar reflex: Should remain present during therapy 3
- Serum magnesium levels: Mandatory monitoring, especially with renal impairment 3
Specific Monitoring in Renal Dysfunction
In severe renal insufficiency, maximum dosage is 20 grams per 48 hours with frequent serum concentration monitoring 3. Geriatric patients often require reduced dosing due to impaired renal function 3.
Multimodal Shivering Management Algorithm
The 2023 European guidelines recommend a stepwise approach 1:
Step 1: Non-Pharmacologic Measures
- Skin counterwarming (extremities, ears, palms, soles)
- Each 4°C increase in mean skin temperature reduces shivering threshold
Step 2: Non-Sedating Adjuncts
- Acetaminophen + Magnesium sulfate (2-4 g bolus, then 1 g/hour infusion)
- Safe but typically insufficient alone
Step 3: Intensify Sedation (if tolerated)
- Meperidine: Most effective opioid (lowers threshold and suppresses shivering)
- Continuous analgesic infusion (fentanyl, remifentanil)
- Sedative infusion (propofol preferred over benzodiazepines)
Step 4: Neuromuscular Blockade
- Most effective abortive measure for shivering 1
- Use short-term NMB (1-2 boluses) during induction phase of TTM
- Continuous infusion if less aggressive measures fail
- Mandatory EEG monitoring during NMB to detect masked seizures 1
Critical Caveats
Limitations of Magnesium Monotherapy
The evidence consistently shows magnesium's modest effect makes it unsuitable as sole therapy 1, 2. A 1991 study comparing pethidine, magnesium sulfate, and droperidol found pethidine most effective, followed by magnesium, with droperidol showing no significant effect 6.
Synergistic Benefits
Magnesium's value lies in combination therapy. When added to meperidine-based regimens, it can enhance cooling rates and improve patient comfort during therapeutic hypothermia 7. The combination of pharmacologic agents can be synergistic, potentially reducing the shivering threshold by 2-3°C 1.
Safety Considerations
- Vasodilation: Can cause hypotension, particularly with rapid infusion
- Calcium availability: Injectable calcium salt should be immediately available to counteract magnesium toxicity 3
- Drug interactions: Potentiates CNS depressants and neuromuscular blocking agents 3
- Pregnancy: Continuous use beyond 5-7 days can cause fetal abnormalities 3
Context-Specific Use
For therapeutic hypothermia after cardiac arrest: Magnesium is recommended as part of the initial multimodal approach during the induction phase, combined with analgesics, sedatives, and surface counterwarming 1. It should be considered prophylactically rather than waiting for shivering to develop.
For postoperative shivering: Higher weight-based doses (25-50 mg/kg) may be more appropriate than the standard 2-4 g bolus used in TTM protocols 5, 4.
The 2025 ERC/ESICM guidelines support using short-acting IV sedatives with daily sedation holds, emphasizing that institutional protocols facilitate consistent stepwise approaches to shivering management 8.